Maxwell Skor, an analyst from Morgan Stanley, maintained the Buy rating on Amicus. The associated price target remains the same with $12.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Maxwell Skor has given his Buy rating due to a combination of factors, including Amicus Therapeutics’ strong financial performance and strategic positioning. The company reported impressive revenue growth in the second quarter of 2025, driven by high compliance rates and new patient starts for its core products, Galafold and PomOp. This growth positions Amicus for GAAP profitability in the latter half of 2025 and projects over $1 billion in total revenue by 2028.
Additionally, the expansion of PomOp in European markets like Spain and the Netherlands, along with the highest demand quarter for Galafold since its launch, underscores the company’s competitive edge and market potential. Management’s confidence in their intellectual property position and the strategic integration of Ireland into their EU supply chain further support the positive outlook. These factors collectively contribute to Skor’s optimistic assessment and Buy rating for Amicus’ stock.
In another report released yesterday, TD Cowen also maintained a Buy rating on the stock with a $20.00 price target.
FOLD’s price has also changed moderately for the past six months – from $9.580 to $5.990, which is a -37.47% drop .